Patent · US Active

Natriuretic peptides and placenta growth factor levels for risk stratification

US7820373B2 · kind B2 · utility

2Cited by

0References

9Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Georg Hess · Mainz, DE
Andrea Horsch · Luzern, CH

Key dates

Filing date	Aug 6, 2008
Grant date	Oct 26, 2010
Priority date	—
Expiry date	Aug 6, 2028

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/32
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of placenta growth factor, wherein (b) if the level of the placenta growth factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.